Association of macrophage inhibitory factor -1 polymorphisms with antiviral efficacy of type 1b chronic hepatitis C
- PMID: 33604810
- PMCID: PMC8119258
- DOI: 10.1007/s11010-021-04097-2
Association of macrophage inhibitory factor -1 polymorphisms with antiviral efficacy of type 1b chronic hepatitis C
Abstract
The expression of macrophage inhibitory factor-1 (MIC-1) increases in patients with chronic hepatitis C (CHC), but whether MIC-1 level and its polymorphism affect the antiviral efficacy of CHC has not yet been reported. The present study aimed to investigate the association between MIC-1 polymorphism and antiviral efficacy in patients with CHC genotype 1b (CHC 1b). A total of 171 patients with CHC1b were recruited. The polymorphisms of rs1059369 and rs1059519 in MIC-1 were detected by DNA sequencing. All patients received a standard dose of polyethylene glycol interferon + ribavirin (PR regimen), and divided into response, nonresponse, sustained virological response (SVR), and non-sustained virological response (NSVR) groups based on HCV RNA levels. The genotype distribution of the two single nucleotide polymorphisms (SNPs) did not differ between the response and nonresponse groups, SVR and non-SVR groups. However, the level of MIC-1 was positively correlated with ALT, AST, PIIINP, CIV, and HCV RNA (P < 0.05). Compared to before treatment, the level of MIC-1 in plasma was significantly decrease in the response group but not in the non-responsive group. Our results suggest that the level of MIC-1 in CHC1b is correlated with liver cell injury, liver fibrosis index, and viral load. However, the polymorphism of rs1059369 and rs1059519 may have negligible impact in expression of MIC-1 and efficacy of antiviral therapy in CHC patient.
Keywords: Antiviral therapy; Chronic hepatitis C; Macrophage inhibitory factor-1; Single nucleotide polymorphisms.
Conflict of interest statement
There are no conflicts of interest.
Figures




Similar articles
-
Associations of content and gene polymorphism of macrophage inhibitory factor-1 and chronic hepatitis C virus infection.World J Gastroenterol. 2020 Nov 7;26(41):6378-6390. doi: 10.3748/wjg.v26.i41.6378. World J Gastroenterol. 2020. PMID: 33244199 Free PMC article.
-
Prevalence of IFNL3 rs4803217 single nucleotide polymorphism and clinical course of chronic hepatitis C.World J Gastroenterol. 2017 Jun 7;23(21):3815-3824. doi: 10.3748/wjg.v23.i21.3815. World J Gastroenterol. 2017. PMID: 28638221 Free PMC article.
-
Interleukin 28B-related polymorphisms: a pathway for understanding hepatitis C virus infection?World J Gastroenterol. 2013 Nov 14;19(42):7399-404. doi: 10.3748/wjg.v19.i42.7399. World J Gastroenterol. 2013. PMID: 24259970 Free PMC article.
-
Role of interleukin 28B-related gene polymorphisms in chronic hepatitis C and the response to antiviral therapy in Koreans.J Clin Gastroenterol. 2013 Aug;47(7):644-50. doi: 10.1097/MCG.0b013e3182896abf. J Clin Gastroenterol. 2013. PMID: 23442843
-
Host factors determining the efficacy of hepatitis C treatment.J Gastroenterol. 2013 Jan;48(1):22-30. doi: 10.1007/s00535-012-0669-x. Epub 2012 Oct 27. J Gastroenterol. 2013. PMID: 23104468 Free PMC article. Review.
References
-
- Chinese Society of Hepatology Chinese Society of Infectious Diseases, guidelines for the prevention and treatment of Hepatitis C (2015 update) Chin J Liver Dis. 2015;3:906–923. - PubMed
-
- WHO. Guidelines for the screening, care and treatment of persons with hepatitis C infection EB/OL. 2014-04 http://www.Who.Int/hepatitis/publications/hepatitis-c-guidelines/en/ - PubMed
Publication types
MeSH terms
Substances
LinkOut - more resources
Full Text Sources
Other Literature Sources
Research Materials